螺内酯对非酒精性脂肪肝药物治疗的影响。

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM
Minerva endocrinology Pub Date : 2023-09-01 Epub Date: 2021-10-20 DOI:10.23736/S2724-6507.21.03564-8
Apostolis Papaefthymiou, Michael Doulberis, Kyriaki Karafyllidou, Eleftherios Chatzimichael, Georgia Deretzi, Aristomenis K Exadaktylos, Fotios Sampsonas, Athanasios Gelasakis, Spyros I Papamichos, Georgios Kotronis, Dimitra Gialamprinou, Elisabeth Vardaka, Stergios A Polyzos, Jannis Kountouras
{"title":"螺内酯对非酒精性脂肪肝药物治疗的影响。","authors":"Apostolis Papaefthymiou,&nbsp;Michael Doulberis,&nbsp;Kyriaki Karafyllidou,&nbsp;Eleftherios Chatzimichael,&nbsp;Georgia Deretzi,&nbsp;Aristomenis K Exadaktylos,&nbsp;Fotios Sampsonas,&nbsp;Athanasios Gelasakis,&nbsp;Spyros I Papamichos,&nbsp;Georgios Kotronis,&nbsp;Dimitra Gialamprinou,&nbsp;Elisabeth Vardaka,&nbsp;Stergios A Polyzos,&nbsp;Jannis Kountouras","doi":"10.23736/S2724-6507.21.03564-8","DOIUrl":null,"url":null,"abstract":"<p><p>Nonalcoholic fatty liver disease (NAFLD) was recently renamed to metabolic (dysfunction)-associated fatty liver disease (MAFLD) to better characterize its pathogenic origin. NAFLD represents, at least in western societies, a potential epidemic with raising prevalence. Its multifactorial pathogenesis is partially unraveled and till now there is no approved pharmacotherapy for NAFLD. A plethora of various choices are investigated in clinical trials, targeting an arsenal of different pathways and molecules. Since the mineralocorticoid receptor (MR) and renin-angiotensin-aldosterone system (RAAS) appear to be implicated in NAFLD, within this concise review, we focus on a rather classical and inexpensive pharmacological agent, spironolactone. We present the current lines of evidence of MR and RAAS-related preclinical models and human trials reporting an association with NAFLD. In conclusion, evidence about spironolactone of RAAS is commented, as potential future pharmacological management of NAFLD.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease.\",\"authors\":\"Apostolis Papaefthymiou,&nbsp;Michael Doulberis,&nbsp;Kyriaki Karafyllidou,&nbsp;Eleftherios Chatzimichael,&nbsp;Georgia Deretzi,&nbsp;Aristomenis K Exadaktylos,&nbsp;Fotios Sampsonas,&nbsp;Athanasios Gelasakis,&nbsp;Spyros I Papamichos,&nbsp;Georgios Kotronis,&nbsp;Dimitra Gialamprinou,&nbsp;Elisabeth Vardaka,&nbsp;Stergios A Polyzos,&nbsp;Jannis Kountouras\",\"doi\":\"10.23736/S2724-6507.21.03564-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Nonalcoholic fatty liver disease (NAFLD) was recently renamed to metabolic (dysfunction)-associated fatty liver disease (MAFLD) to better characterize its pathogenic origin. NAFLD represents, at least in western societies, a potential epidemic with raising prevalence. Its multifactorial pathogenesis is partially unraveled and till now there is no approved pharmacotherapy for NAFLD. A plethora of various choices are investigated in clinical trials, targeting an arsenal of different pathways and molecules. Since the mineralocorticoid receptor (MR) and renin-angiotensin-aldosterone system (RAAS) appear to be implicated in NAFLD, within this concise review, we focus on a rather classical and inexpensive pharmacological agent, spironolactone. We present the current lines of evidence of MR and RAAS-related preclinical models and human trials reporting an association with NAFLD. In conclusion, evidence about spironolactone of RAAS is commented, as potential future pharmacological management of NAFLD.</p>\",\"PeriodicalId\":18690,\"journal\":{\"name\":\"Minerva endocrinology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Minerva endocrinology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23736/S2724-6507.21.03564-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/10/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S2724-6507.21.03564-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 3

摘要

非酒精性脂肪肝(NAFLD)最近被重命名为代谢(功能障碍)相关脂肪肝(MAFLD),以更好地描述其病因。至少在西方社会,NAFLD是一种潜在的流行病,患病率不断上升。其多因素发病机制已被部分阐明,迄今为止还没有批准的NAFLD药物治疗方法。临床试验中研究了大量不同的选择,针对不同的途径和分子。由于盐皮质激素受体(MR)和肾素-血管紧张素-醛固酮系统(RAAS)似乎与NAFLD有关,在这篇简要的综述中,我们将重点关注一种相当经典且廉价的药物,螺内酯。我们介绍了目前MR和RAAS相关临床前模型和人体试验的证据,这些模型和试验报告了与NAFLD的相关性。总之,关于RAAS的螺内酯的证据被评论为NAFLD潜在的未来药理学治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease.

Nonalcoholic fatty liver disease (NAFLD) was recently renamed to metabolic (dysfunction)-associated fatty liver disease (MAFLD) to better characterize its pathogenic origin. NAFLD represents, at least in western societies, a potential epidemic with raising prevalence. Its multifactorial pathogenesis is partially unraveled and till now there is no approved pharmacotherapy for NAFLD. A plethora of various choices are investigated in clinical trials, targeting an arsenal of different pathways and molecules. Since the mineralocorticoid receptor (MR) and renin-angiotensin-aldosterone system (RAAS) appear to be implicated in NAFLD, within this concise review, we focus on a rather classical and inexpensive pharmacological agent, spironolactone. We present the current lines of evidence of MR and RAAS-related preclinical models and human trials reporting an association with NAFLD. In conclusion, evidence about spironolactone of RAAS is commented, as potential future pharmacological management of NAFLD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.60
自引率
0.00%
发文量
146
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信